NCT00595101

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

A Phase 2, 28-Day Parallel-Group, Double-Masked, Dose Finding Study Comparing The Safety And Efficacy Of PF-03187207 To Latanoprost In Patients With Primary Open Angle Glaucoma Or Ocular Hypertension.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 117 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension

Conditions

• Primary Open Angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	PF-03187207
DRUG	Latanoprost 0.005%
DRUG	PF-03187207 Vehicle	One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207.
DRUG	Latanoprost Vehicle

Timeline

• Start date: 2007-12-01
• Primary completion: 2008-06-01
• Completion: 2008-06-01
• First posted: 2008-01-16
• Last updated: 2020-09-14
• Results posted: 2020-08-27

Locations

13 sites across 1 country: Japan